ResearcherTUM KlinikumNo recent work listed
Sandra Diersch
Matched on OpenAlex author ID A5033410393. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 3
- AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. First author DOI 10.1007/s00018-022-04638-y↗
- Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Co-author DOI 10.18632/oncotarget.859↗
- Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1593/neo.111016↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Günter Schneider · 3 shared papers, 2011–2022 · strength 0.18
- Paper AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. DOI 10.1007/s00018-022-04638-y↗
- Paper Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinic… DOI 10.18632/oncotarget.859↗
- Paper Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. DOI 10.1593/neo.111016↗
- Dieter Saur · 3 shared papers, 2011–2022 · strength 0.18
- Paper AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. DOI 10.1007/s00018-022-04638-y↗
- Paper Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinic… DOI 10.18632/oncotarget.859↗
- Paper Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. DOI 10.1593/neo.111016↗
- Maximilian Reichert · 2 shared papers, 2013–2022 · strength 0.15
- Christian Schneeweis · 1 shared paper, 2022 · strength 0.12
- Chiara Falcomatà · 1 shared paper, 2022 · strength 0.12
- Marian Grade · 1 shared paper, 2022 · strength 0.12
- Daniele Lucarelli · 1 shared paper, 2022 · strength 0.12
- Alexander Arlt · 1 shared paper, 2022 · strength 0.12
- Zonera Hassan · 1 shared paper, 2022 · strength 0.12
- Lukas Krauß · 1 shared paper, 2022 · strength 0.12
- Carolin Schneider · 1 shared paper, 2022 · strength 0.12
- Oliver Holger Krämer · 1 shared paper, 2022 · strength 0.12
- Roland Rad · 1 shared paper, 2022 · strength 0.12
- Elisabeth Heßmann · 1 shared paper, 2022 · strength 0.12
- Matthias Wirth · 1 shared paper, 2022 · strength 0.12
- Stefan Eser · 2 shared papers, 2011–2013 · strength 0.05
- Roland Michael Schmid · 2 shared papers, 2011–2013 · strength 0.05
- Iréne Esposito · 1 shared paper, 2013 · strength 0.03
- Laura Conradt · 1 shared paper, 2011 · strength 0.02
- Christoph W. Michalski · 1 shared paper, 2011 · strength 0.02
- Jorg H. Kleeff · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.